Back to today’s briefing

Story perspectives

Analysts Boost Buy Ratings for Altimmune, Dogwood Therapeutics

11/10/2025

44 10

Summary

Story summary

Patrick Trucchio of H.C. Wainwright reaffirmed a Buy rating for Altimmune (ALT) with a $12.00 target, while consensus shows a Strong Buy with an $18.60 target and ~374.5% upside.
Citizens JMP maintained a Buy rating with a $14.00 target on Altimmune.
Jason McCarthy of Maxim Group set a Buy for Dogwood Therapeutics (DWTX) at $30.00, while the stock closed at $5.26 and the consensus remains a Moderate Buy at $21.00.

1 of 1

Story summary

Patrick Trucchio of H.C. Wainwright reaffirmed a Buy rating for Altimmune (ALT) with a $12.00 target, while consensus shows a Strong Buy with an $18.60 target and ~374.5% upside.
Citizens JMP maintained a Buy rating with a $14.00 target on Altimmune.
Jason McCarthy of Maxim Group set a Buy for Dogwood Therapeutics (DWTX) at $30.00, while the stock closed at $5.26 and the consensus remains a Moderate Buy at $21.00.